<DOC>
	<DOCNO>NCT01294540</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics E2609 administer single dos healthy adult volunteer healthy elderly subject . The study consist 2 part : ( 1 ) single dose healthy adult volunteer , dose 800 mg maximum dose tolerate , ( 2 ) single dose 50 mg healthy elderly volunteer .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E2609 Healthy Subjects Elderly Cohort</brief_title>
	<detailed_description>The study consist 2 part : ( 1 ) single dose healthy adult volunteer , dose 100 mg maximum dose tolerate , ( 2 ) single dose 25 mg low healthy elderly volunteer .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion : Healthy male female Aged 30 55 year , inclusive ( Cohorts 1 5 ) ; age 65 85 year , inclusive ( Cohort 6 ) Body mass index ( BMI ) 18 32kg/m^2 Screening Additional inclusion criterion Cohort 6 ( healthy elderly subject ) Exclusion Females childbearing potential Personal family history neurological abnormality Any clinical abnormality electrocardiogram ( ECG ) Screening checkin A family history cardiac abnormality Thyroid abnormality</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>